Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
DJ Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
By Cecilia Butini
Shares in French biopharmaceutical group Ipsen rose on Wednesday after the company said the European Commission has given the green light to the company's drug Cabometyx in combination with Bristol Myers Squibb Co.'s Opdivo for the treatment of renal cell carcinoma, a type of kidney cancer.
At 0900 GMT, Ipsen shares traded 4.4% higher at EUR73.05.
The company said the EU approval is based on results from a phase-3 trial named CheckMate-9ER, whose primary endpoint was the median progression-free survival in patients receiving the drug combination.
Progression-free survival--which is understood as the time after treatment that a patient can live without the disease worsening--was observed as doubling in patients receiving the drug combination compared with those receiving another, previously approved drug.
EU approval means the drug combination can be marketed for renal cell carcinoma in EU member states, Norway, Liechtenstein and Iceland, while the U.S. already granted approval in January, Ipsen said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 31, 2021 05:08 ET (09:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
DJ Ipsen在欧盟批准肾癌药物组合后交易走高
By Cecilia Butini
塞西莉亚·布蒂尼(Cecilia Butini)
Shares in French biopharmaceutical group Ipsen rose on Wednesday after the company said the European Commission has given the green light to the company's drug Cabometyx in combination with Bristol Myers Squibb Co.'s Opdivo for the treatment of renal cell carcinoma, a type of kidney cancer.
法国生物制药集团益普森(Ipsen)股价周三上涨，此前该公司表示，欧盟委员会已批准该公司的药物Cabometyx与百时美施贵宝(Bristol Myers Squibb Co.)的Opdivo联合用于治疗肾癌，肾癌是肾癌的一种。
At 0900 GMT, Ipsen shares traded 4.4% higher at EUR73.05.
格林威治时间0900时，Ipsen股价上涨4.4%，至73.05欧元。
The company said the EU approval is based on results from a phase-3 trial named CheckMate-9ER, whose primary endpoint was the median progression-free survival in patients receiving the drug combination.
该公司表示，欧盟的批准是基于名为CheckMate-9ER的3期试验的结果，该试验的主要终点是接受联合药物治疗的患者的中位无进展生存率。
Progression-free survival--which is understood as the time after treatment that a patient can live without the disease worsening--was observed as doubling in patients receiving the drug combination compared with those receiving another, previously approved drug.
无进展存活率--被认为是患者在治疗后可以存活而不会恶化的时间--被观察到，与接受另一种先前批准的药物的患者相比，接受这种药物组合的患者增加了一倍。
EU approval means the drug combination can be marketed for renal cell carcinoma in EU member states, Norway, Liechtenstein and Iceland, while the U.S. already granted approval in January, Ipsen said.
Ipsen说，欧盟的批准意味着该药物组合可以在欧盟成员国、挪威、列支敦士登和冰岛销售治疗肾癌的药物，而美国已经在1月份批准了这种药物。
Write to Cecilia Butini at cecilia.butini@wsj.com
写信给塞西莉亚·布蒂尼(Cecilia Butini)，电子邮件：cecilia.butini@wsj.com
(END) Dow Jones Newswires
(完)道琼通讯社
March 31, 2021 05:08 ET (09:08 GMT)
2021年3月31日东部时间05：08(格林尼治标准时间09：08)
Copyright (c) 2021 Dow Jones & Company, Inc.
版权所有(C)2021年道琼斯公司
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧